We’re here to help.
Our friendly team is available to help Monday to Friday 9:00am – 5:00pm.
If you need urgent assistance, do not use this service. Call 111, or in an emergency call 999.
Our friendly team is available to help Monday to Friday 9:00am – 5:00pm.
If you need urgent assistance, do not use this service. Call 111, or in an emergency call 999.
0 items in your cart
Fast, discreet delivery
Free delivery over £40
100% UK-based pharmacy
All doctors & pharmacists UK-based
Free advice & support
Clinical support free · Mon–Fri 9am–5pm
Why Patients Choose Access Doctor
10+
Years serving UK patients
2,000+
Verified patient reviews
1,000+
Licensed treatments
24/7
Consultation available
Foundayo tablets (orforglipron) is a once-daily prescription tablet licensed for weight management in adults with obesity (BMI 30 or above) or overweight (BMI 27 or above) with a weight-related health condition.
Order before 3pm — same-day dispatch (MON - FRI)
~5 min consultation
Suitable age
18 years +
Max per order
1 pack
Consultation
Yes, free online
Foundayo is the brand name for orforglipron, a once-daily tablet made by Eli Lilly. The MHRA authorised it on 10 August 2026, making the UK the first country in Europe to license it.
It belongs to the same family of medicines as Wegovy and Mounjaro, the GLP-1 receptor agonists. These work with your body's own appetite signals: they slow how quickly your stomach empties and reduce hunger, so you feel full sooner and stay full for longer. Eating less becomes easier to sustain, rather than something you have to fight.
What makes Foundayo different is its chemistry. Wegovy and Mounjaro are peptides, which is why they are given as injections. Orforglipron is a small molecule instead, so it survives digestion and can be taken as an ordinary tablet.
That has one practical consequence patients notice most: you can take it at any time of day, with or without food, and you do not need to wait before eating or drinking. Foundayo is a prescription-only medicine, licensed to be used alongside a reduced-calorie diet and increased physical activity. It is not currently available on the NHS.
| Active ingredient | Orforglipron |
| Brand name | Foundayo |
| Manufacturer | Eli Lilly |
| Medicine class | GLP-1 receptor agonist (non-peptide) |
| How it is taken | One tablet once daily, any time of day |
| Food restrictions | None |
| Licensed for | Weight management and type 2 diabetes blood sugar control |
| Eligibility | BMI 30 or above, or 27 or above with a weight-related condition |
| UK authorisation | MHRA, 10 August 2026 |
| NHS availability | Not available on the NHS |
| Prescription status | Prescription-only medicine (POM) |
Foundayo (orforglipron) is a prescription-only, once-daily tablet licensed in the UK for two indications: weight management in adults, and improving blood sugar control in adults with type 2 diabetes.
For weight management, Foundayo is licensed for adults with a BMI of 30 kg/m2 or above (obesity), or a BMI of 27 kg/m2 or above (overweight) in the presence of at least one weight-related health condition such as type 2 diabetes, high blood pressure, raised cholesterol, obstructive sleep apnoea or cardiovascular disease. It is used as an adjunct to a reduced-calorie diet and increased physical activity, not as a replacement for them.
Foundayo is made by Eli Lilly and was authorised by the MHRA on 10 August 2026, making the United Kingdom the first country in Europe to license it. It is the first non-peptide GLP-1 receptor agonist authorised here, and that difference in chemistry is what allows it to be taken as an ordinary tablet rather than by injection.
Foundayo is not currently available on the NHS. NICE guidance on orforglipron for managing overweight and obesity is expected on 18 November 2026. Until then it is available privately, on prescription, following a clinical consultation with a UK-registered prescriber.
It is a tablet rather than an injection, and it is taken once a day rather than once a week. All three work on the same appetite pathway, but Foundayo's different chemistry is what allows it to be swallowed rather than injected.
No. That requirement applies to oral semaglutide, not to Foundayo. You can take Foundayo at any time of day, with or without food, and eat and drink normally afterwards.
No. NICE guidance on orforglipron for overweight and obesity is due to be published on 18 November 2026, and NHS availability would follow from that.
It is licensed for adults with a BMI of 30 or above, or a BMI of 27 or above with a weight-related health condition such as type 2 diabetes, high blood pressure or high cholesterol. A prescriber will assess your suitability during your consultation.
Nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain. They are usually most noticeable after a dose increase and often ease as your body adjusts.
Obesity is a long-term condition, and appetite signals return to their previous pattern when GLP-1 treatment stops. Your prescriber will discuss how long treatment is likely to continue and what happens afterwards.
No reviews yet. Be the first to write one.
Helpful articles and clinical guides related to this treatment category.
Free consultation
Online review by a UK prescriber
Next-day delivery
Order before 3pm where offered
Discreet packaging
Plain outer packaging
